ATE549355T1 - Zusammensetzungen die grosse und kleine gegen das selbe toxin gerichtete antikkörperfragmente enthalten - Google Patents
Zusammensetzungen die grosse und kleine gegen das selbe toxin gerichtete antikkörperfragmente enthaltenInfo
- Publication number
- ATE549355T1 ATE549355T1 AT04735923T AT04735923T ATE549355T1 AT E549355 T1 ATE549355 T1 AT E549355T1 AT 04735923 T AT04735923 T AT 04735923T AT 04735923 T AT04735923 T AT 04735923T AT E549355 T1 ATE549355 T1 AT E549355T1
- Authority
- AT
- Austria
- Prior art keywords
- compositions containing
- antibody fragments
- directed against
- toxin
- containing large
- Prior art date
Links
- 239000003053 toxin Substances 0.000 title abstract 4
- 231100000765 toxin Toxicity 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 title 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 title 1
- 108700012359 toxins Proteins 0.000 abstract 3
- 230000027455 binding Effects 0.000 abstract 2
- 239000011230 binding agent Substances 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 230000009870 specific binding Effects 0.000 abstract 2
- 108030001720 Bontoxilysin Proteins 0.000 abstract 1
- 231100000573 exposure to toxins Toxicity 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 231100000572 poisoning Toxicity 0.000 abstract 1
- 230000000607 poisoning effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0312642.2A GB0312642D0 (en) | 2003-06-03 | 2003-06-03 | Pharmaceutical composition |
| PCT/GB2004/002351 WO2004106376A1 (en) | 2003-06-03 | 2004-06-03 | Compositions comprising large and small binding fragments of antibodies against the same toxin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE549355T1 true ATE549355T1 (de) | 2012-03-15 |
Family
ID=9959179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04735923T ATE549355T1 (de) | 2003-06-03 | 2004-06-03 | Zusammensetzungen die grosse und kleine gegen das selbe toxin gerichtete antikkörperfragmente enthalten |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7618625B2 (de) |
| EP (1) | EP1629009B8 (de) |
| JP (1) | JP5065677B2 (de) |
| AT (1) | ATE549355T1 (de) |
| AU (1) | AU2004242760B2 (de) |
| DK (1) | DK1629009T3 (de) |
| GB (1) | GB0312642D0 (de) |
| WO (1) | WO2004106376A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7563874B2 (en) | 1998-08-31 | 2009-07-21 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| CN101146554B (zh) | 2005-01-27 | 2012-10-10 | 加州大学评议会 | 中和肉毒杆菌神经毒素的治疗性单克隆抗体 |
| GB2442466A (en) * | 2006-10-06 | 2008-04-09 | Secr Defence | Method of producing antibodies against toxins |
| WO2008041012A1 (en) * | 2006-10-06 | 2008-04-10 | The Secretary Of State For Defence | Pharmaceutical composition comprising antibodies against a toxin |
| CA2680741A1 (en) | 2007-03-22 | 2009-01-15 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| US9000131B2 (en) | 2008-07-31 | 2015-04-07 | The Regents Of The University Of California | Antibodies that neutralize botulinum neurotoxins |
| WO2012047427A2 (en) | 2010-08-31 | 2012-04-12 | The Regents Of The University Of California | Antibodies for botulinum neurotoxins |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE529530T1 (de) * | 2001-11-05 | 2011-11-15 | Univ Texas | Rekombinante antikörper zum nachweis und zur neutralisierung von milzbrandtoxin |
| US20050042775A1 (en) * | 2003-08-21 | 2005-02-24 | Nicholas Pomato | Botulinum antitoxin compositions and methods |
-
2003
- 2003-06-03 GB GBGB0312642.2A patent/GB0312642D0/en not_active Ceased
-
2004
- 2004-06-03 JP JP2006508389A patent/JP5065677B2/ja not_active Expired - Lifetime
- 2004-06-03 DK DK04735923.7T patent/DK1629009T3/da active
- 2004-06-03 US US10/559,148 patent/US7618625B2/en not_active Expired - Lifetime
- 2004-06-03 EP EP04735923A patent/EP1629009B8/de not_active Expired - Lifetime
- 2004-06-03 AU AU2004242760A patent/AU2004242760B2/en not_active Expired
- 2004-06-03 WO PCT/GB2004/002351 patent/WO2004106376A1/en not_active Ceased
- 2004-06-03 AT AT04735923T patent/ATE549355T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| US7618625B2 (en) | 2009-11-17 |
| DK1629009T3 (da) | 2012-05-29 |
| AU2004242760B2 (en) | 2007-12-20 |
| JP2007527372A (ja) | 2007-09-27 |
| EP1629009B8 (de) | 2012-04-18 |
| EP1629009B1 (de) | 2012-03-14 |
| WO2004106376A1 (en) | 2004-12-09 |
| EP1629009A1 (de) | 2006-03-01 |
| US20070036805A1 (en) | 2007-02-15 |
| JP5065677B2 (ja) | 2012-11-07 |
| GB0312642D0 (en) | 2003-07-09 |
| AU2004242760A1 (en) | 2004-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0506726B8 (pt) | anticorpo monoclonal específico para m-csf e usos deste | |
| EA201201533A1 (ru) | Prlr-специфическое антитело и его применения | |
| BR0207068A (pt) | Anticorpo monoclonal para a protéina clfa, anti-soro isolado, anticorpo isolado e anticorpo humanizado contendo o referido anticorpo, kit diagnóstico compreendendo o referido anticorpo, método para diagnóstico de uma infecção por s.aureus, composição farmacêutica para o tratamento ou prevenção da referida infecção, método para indução de de uma resposta imunológica, método para identificação de anticorpos monoclonais para a protéina clfa e fragmento ativo isolado a partir do domìnio a da protéina clfa do s.aureus | |
| EA200801509A1 (ru) | Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7 | |
| BR0209689A (pt) | Uso de fragmento de hmg como agente anti-inflamatório | |
| BRPI0408317A (pt) | anticorpos do receptor de igf-i para o tratamento de cáncer | |
| NO20050795L (no) | Forbindelser, blandinger og fremgangsmater for utnyttelse av samme | |
| BRPI0513681A (pt) | composição que compreendem anticorpo her2, método, formulações farmacêuticas, polipeptìdeo, anticorpo e método de tratamento de cáncer | |
| EA201100694A1 (ru) | Антитело к cd38 человека и его применение | |
| EP1844077A4 (de) | Dr5-antikörper und deren verwendung | |
| EP2153848A3 (de) | Monoklonale therapeutische Antikörper zur Neutralisierung von Botulin-Neurotoxinen | |
| MA30353B1 (fr) | Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes. | |
| DE60321041D1 (de) | Antikörper gegen krebsantigen tmeff2 und seine anwendungen | |
| ATE517920T1 (de) | Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1) | |
| WO2008079270A3 (en) | Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis | |
| MX2009001341A (es) | Anticuerpos especificos de ephb3 y usos de los mismos. | |
| MX2022015966A (es) | Anticuerpos y metodos para tratar enfermedades asociadas a claudina. | |
| ATE549355T1 (de) | Zusammensetzungen die grosse und kleine gegen das selbe toxin gerichtete antikkörperfragmente enthalten | |
| BRPI0612840A8 (pt) | Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções | |
| WO2021207948A9 (en) | Anti-sars-cov-2 antibodies and uses thereof | |
| ECSP055849A (es) | Anticuerpo ("11c7") anti-nogo a y su uso farmacéutico | |
| ATE335739T1 (de) | Cak inhibitoren und deren verwendungen | |
| WO2022170008A3 (en) | Anti-il1rap antibodies | |
| EP2436774A3 (de) | Therapeutische monoklonale Antikörper zur Neutralisierung von Botulinumneurotoxinen | |
| DE602008002692D1 (de) | Topische antibiotische zusammensetzung zur prävention von lyme-borreliose |